News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
91,556 Results
Type
Article (6737)
Company Profile (42)
Press Release (84777)
Section
Business (28046)
Career Advice (126)
Deals (4052)
Drug Delivery (31)
Drug Development (14123)
Employer Resources (12)
FDA (2832)
Job Trends (2121)
News (49603)
Policy (6037)
Tag
Academia (423)
Allergies (21)
Alliances (9047)
Alzheimer's disease (235)
Antibody-drug conjugate (ADC) (24)
Approvals (2816)
Artificial intelligence (21)
Bankruptcy (18)
Best Places to Work (1785)
BIOSECURE Act (17)
Biosimilars (52)
Biotechnology (30)
Breast cancer (22)
Cancer (222)
Career advice (109)
Cell therapy (49)
Clinical research (11169)
Collaboration (85)
Compensation (17)
COVID-19 (529)
C-suite (23)
Data (222)
Diabetes (20)
Diagnostics (517)
Drug pricing (16)
Earnings (9293)
Events (11556)
Executive appointments (40)
FDA (2981)
Funding (61)
Gene therapy (51)
GLP-1 (99)
Government (1295)
Healthcare (1947)
Immunology and inflammation (19)
Infectious disease (546)
Inflammatory bowel disease (40)
IPO (1842)
Job creations (392)
Job search strategy (107)
Layoffs (48)
Legal (562)
Lung cancer (53)
Manufacturing (71)
Medical device (1167)
Medtech (1168)
Mergers & acquisitions (2253)
Metabolic disorders (46)
Neuroscience (276)
NextGen Class of 2024 (707)
Non-profit (346)
Northern California (274)
Obesity (16)
Opinion (41)
Patents (13)
Peanut (18)
People (7897)
Phase I (3675)
Phase II (4656)
Phase III (4077)
Pipeline (131)
Policy (31)
Postmarket research (293)
Preclinical (1440)
Press Release (66)
Radiopharmaceuticals (34)
Rare diseases (34)
Real estate (951)
Regulatory (4586)
Research institute (386)
Southern California (288)
Startups (594)
United States (2438)
Vaccines (140)
Date
Last 7 days (191)
Last 30 days (651)
Last 365 days (6587)
2024 (5990)
2023 (7010)
2022 (9138)
2021 (9554)
2020 (8235)
2019 (5900)
2018 (4586)
2017 (5125)
2016 (4673)
2015 (5356)
2014 (3763)
2013 (2946)
2012 (3015)
2011 (3176)
2010 (2615)
Location
Africa (92)
Asia (7854)
Australia (867)
California (637)
Canada (156)
China (98)
Colorado (23)
Delaware (16)
Europe (13604)
Florida (70)
Idaho (13)
Illinois (30)
Indiana (25)
Maryland (228)
Massachusetts (426)
Minnesota (36)
New Jersey (272)
New York (176)
North Carolina (147)
Northern California (274)
Ohio (27)
Pennsylvania (115)
South America (135)
Southern California (288)
Texas (70)
Washington State (53)
91,556 Results for "wuxi biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BIOSECURE Act
WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow
WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.
October 8, 2024
·
5 min read
·
Ben Hargreaves
China
WuXi Biologics Takes Net Profit Hit Despite Inking Record Number of New Projects
With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.
August 22, 2024
·
2 min read
·
Tristan Manalac
BIOSECURE Act
WuXi Mulls Sale of Some US, European Operations: FT
The
Financial Times
reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe.
October 3, 2024
·
2 min read
·
Tristan Manalac
Podcast
BioSpace
at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
Cell and gene therapy investment rebounds; WuXi Biologics and other companies named in BIOSECURE Act mull options; Bayer, J&J and Pfizer’s recent layoffs; updates from the weight loss space.
October 9, 2024
·
1 min read
·
Heather McKenzie
BIOSECURE Act
WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms
With the BIOSECURE Act likely to be voted on in Congress this year, WuXi AppTec’s U.S. revenue dropped 1.2% in the first half of 2024 while the Chinese company increased its lobbying efforts.
July 29, 2024
·
2 min read
·
Tyler Patchen
Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs
As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.
July 3, 2024
·
4 min read
·
Tyler Patchen
Policy
Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs
As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.
June 25, 2024
·
6 min read
·
Tyler Patchen
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
Myricx Bio and WuXi Biologics announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms.
November 21, 2023
·
4 min read
Press Releases
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
August 8, 2024
·
6 min read
BIOSECURE Act
BIOSECURE Act Sails Through House Passage, Lines Up Senate Vote
The U.S. House of Representatives on Monday overwhelmingly passed the bipartisan bill, which targets WuXi AppTec, WuXi Biologics and other Chinese biotech companies as potential national security risks.
September 10, 2024
·
2 min read
·
Tristan Manalac
1 of 9,156
Next
